PT2224917T - Composição que compreende nicotina e opipramol e utilização da mesma - Google Patents
Composição que compreende nicotina e opipramol e utilização da mesmaInfo
- Publication number
- PT2224917T PT2224917T PT88555172T PT08855517T PT2224917T PT 2224917 T PT2224917 T PT 2224917T PT 88555172 T PT88555172 T PT 88555172T PT 08855517 T PT08855517 T PT 08855517T PT 2224917 T PT2224917 T PT 2224917T
- Authority
- PT
- Portugal
- Prior art keywords
- opipramol
- nicotine
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99016107P | 2007-11-26 | 2007-11-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2224917T true PT2224917T (pt) | 2017-10-17 |
Family
ID=40380297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT88555172T PT2224917T (pt) | 2007-11-26 | 2008-11-26 | Composição que compreende nicotina e opipramol e utilização da mesma |
Country Status (21)
Country | Link |
---|---|
US (5) | US8273731B2 (pt) |
EP (1) | EP2224917B1 (pt) |
JP (1) | JP5456687B2 (pt) |
KR (1) | KR101613742B1 (pt) |
CN (1) | CN101925352B (pt) |
AR (1) | AR069752A1 (pt) |
AU (1) | AU2008331102B2 (pt) |
BR (1) | BRPI0819911A2 (pt) |
CA (1) | CA2744736C (pt) |
CL (1) | CL2008003507A1 (pt) |
CY (1) | CY1119768T1 (pt) |
DK (1) | DK2224917T3 (pt) |
ES (1) | ES2642873T3 (pt) |
HR (1) | HRP20171476T1 (pt) |
HU (1) | HUE035105T2 (pt) |
LT (1) | LT2224917T (pt) |
MX (1) | MX2010005804A (pt) |
PL (1) | PL2224917T3 (pt) |
PT (1) | PT2224917T (pt) |
SI (1) | SI2224917T1 (pt) |
WO (1) | WO2009069126A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
WO2010014760A1 (en) | 2008-08-01 | 2010-02-04 | Zoran Corporation | Video encoder with an integrated temporal filter for denoising |
US9801865B2 (en) * | 2008-09-24 | 2017-10-31 | The United States Of America As Represented By The Department Of Veteran Affairs | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation |
US8529914B2 (en) * | 2010-06-28 | 2013-09-10 | Richard C. Fuisz | Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive |
ES2605814T3 (es) | 2011-04-29 | 2017-03-16 | Moberg Pharma Ab | Composiciones farmacéuticas que comprenden un anestésico local tal como bupivacaína para administración local en la boca o la garganta |
WO2014012054A1 (en) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
BR112016021034A8 (pt) | 2014-03-13 | 2021-06-29 | Neuroderm Ltd | composição farmacêutica, uso da mesma e kit |
US20170216273A1 (en) * | 2014-05-29 | 2017-08-03 | Jory F. Goodman | Nicotine Derivatives and Methods of Use |
WO2016042413A1 (en) * | 2014-09-18 | 2016-03-24 | Neuroderm, Ltd. | Opipramol patch |
US9597284B2 (en) | 2014-10-20 | 2017-03-21 | Oyster Point Pharma, Inc. | Dry eye treatments |
MX2017007042A (es) | 2014-12-05 | 2018-06-15 | Juul Labs Inc | Control de dosis calibrada. |
CN114432313A (zh) | 2016-04-07 | 2022-05-06 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
US10292977B2 (en) * | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
US10639300B2 (en) * | 2016-04-12 | 2020-05-05 | Arturo Solis Herrera | Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists |
WO2018097629A1 (ko) * | 2016-11-24 | 2018-05-31 | 에스케이케미칼 주식회사 | 바레니클린 서방성 제제 및 이의 제조 방법 |
WO2018150276A2 (en) | 2017-02-16 | 2018-08-23 | Universidad San Sebastian | The combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological conditions |
US20200000822A1 (en) * | 2017-02-23 | 2020-01-02 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
US10961296B2 (en) * | 2017-11-10 | 2021-03-30 | Howard Hughes Medical Institute | Modified ligand-gated ion channels and methods of use |
LU101519B1 (en) * | 2019-12-02 | 2021-06-07 | Herrera Arturo Solis | (S)-3-[1-MethyIpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a solid substance and a tablet |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5069094A (en) * | 1987-09-08 | 1991-12-03 | Birkestrand Orville J | Tube end finishing machine |
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
WO1993023045A1 (en) * | 1992-05-18 | 1993-11-25 | Pharmaco Behavioral Associates, Inc. | Use of cotinine to alleviate tobacco withdrawal syndrome |
JPH09262287A (ja) * | 1996-03-28 | 1997-10-07 | Terumo Corp | 薬液注入装置 |
WO1998009523A1 (en) * | 1996-09-05 | 1998-03-12 | Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
DE10018834A1 (de) * | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
ATE355854T1 (de) * | 2000-08-03 | 2007-03-15 | Antares Pharma Ipl Ag | Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel |
US6479076B2 (en) * | 2001-01-12 | 2002-11-12 | Izhak Blank | Nicotine delivery compositions |
DE10134038A1 (de) | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
US20030119879A1 (en) | 2001-10-15 | 2003-06-26 | Thomas Landh | Nicotine and chocolate compositions |
US6852741B2 (en) * | 2001-12-31 | 2005-02-08 | University Of Florida | Compositions and methods for treatment of neurological disorders |
US7045534B2 (en) * | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
DK1587506T3 (da) * | 2002-12-18 | 2008-11-24 | Algorx | Administration af capsaicinoider |
ITMI20030828A1 (it) | 2003-04-18 | 2004-10-19 | Farchemia Srl | Procedimento per la preparazione dell'opipramolo. |
PL1670433T3 (pl) * | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
EP1763337A2 (en) * | 2003-12-31 | 2007-03-21 | Actavis Group HF | Immediate, controlled and sustained release formulations of galanthamine |
US20050234024A1 (en) * | 2004-04-14 | 2005-10-20 | Clarke David E | Materials and methods for the treatment of ulcerative colitis |
WO2005115471A2 (en) | 2004-05-27 | 2005-12-08 | Neurocure Ltd. | Methods and compositions for treatment of nicotine dependence and dementias |
US20060142349A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor |
US20080014252A1 (en) * | 2006-07-14 | 2008-01-17 | Delprete Keith | Topical compositions with long lasting effect |
WO2008011484A2 (en) | 2006-07-18 | 2008-01-24 | Bethesda Pharmacology Associates, Llc | Nicotinic desensitizers and methods of selecting, testing, and using them |
WO2008028903A2 (en) * | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
-
2008
- 2008-11-25 CL CL2008003507A patent/CL2008003507A1/es unknown
- 2008-11-26 ES ES08855517.2T patent/ES2642873T3/es active Active
- 2008-11-26 DK DK08855517.2T patent/DK2224917T3/en active
- 2008-11-26 HU HUE08855517A patent/HUE035105T2/en unknown
- 2008-11-26 EP EP08855517.2A patent/EP2224917B1/en not_active Not-in-force
- 2008-11-26 PL PL08855517T patent/PL2224917T3/pl unknown
- 2008-11-26 JP JP2010534598A patent/JP5456687B2/ja not_active Expired - Fee Related
- 2008-11-26 CA CA2744736A patent/CA2744736C/en not_active Expired - Fee Related
- 2008-11-26 LT LTEP08855517.2T patent/LT2224917T/lt unknown
- 2008-11-26 CN CN200880126096.9A patent/CN101925352B/zh not_active Expired - Fee Related
- 2008-11-26 WO PCT/IL2008/001546 patent/WO2009069126A1/en active Application Filing
- 2008-11-26 AU AU2008331102A patent/AU2008331102B2/en not_active Ceased
- 2008-11-26 PT PT88555172T patent/PT2224917T/pt unknown
- 2008-11-26 MX MX2010005804A patent/MX2010005804A/es active IP Right Grant
- 2008-11-26 BR BRPI0819911A patent/BRPI0819911A2/pt not_active IP Right Cessation
- 2008-11-26 AR ARP080105141A patent/AR069752A1/es not_active Application Discontinuation
- 2008-11-26 SI SI200831872T patent/SI2224917T1/sl unknown
- 2008-11-26 US US12/323,779 patent/US8273731B2/en not_active Expired - Fee Related
- 2008-11-26 KR KR1020107014088A patent/KR101613742B1/ko not_active IP Right Cessation
-
2012
- 2012-08-24 US US13/593,911 patent/US8921356B2/en not_active Expired - Fee Related
-
2014
- 2014-11-26 US US14/554,660 patent/US20150306109A1/en not_active Abandoned
-
2016
- 2016-09-08 US US15/259,752 patent/US20170128432A1/en not_active Abandoned
-
2017
- 2017-10-04 HR HRP20171476TT patent/HRP20171476T1/hr unknown
- 2017-10-04 CY CY20171101027T patent/CY1119768T1/el unknown
- 2017-11-30 US US15/827,293 patent/US20180303818A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP5456687B2 (ja) | 2014-04-02 |
BRPI0819911A2 (pt) | 2017-06-13 |
CA2744736C (en) | 2015-06-09 |
KR101613742B1 (ko) | 2016-04-19 |
US8273731B2 (en) | 2012-09-25 |
LT2224917T (lt) | 2017-12-27 |
EP2224917B1 (en) | 2017-07-05 |
CL2008003507A1 (es) | 2009-11-27 |
WO2009069126A1 (en) | 2009-06-04 |
AR069752A1 (es) | 2010-02-17 |
AU2008331102B2 (en) | 2014-04-10 |
CN101925352B (zh) | 2016-03-16 |
MX2010005804A (es) | 2010-11-30 |
AU2008331102A1 (en) | 2009-06-04 |
US20150306109A1 (en) | 2015-10-29 |
HUE035105T2 (en) | 2018-05-02 |
ES2642873T3 (es) | 2017-11-20 |
US8921356B2 (en) | 2014-12-30 |
CY1119768T1 (el) | 2018-06-27 |
DK2224917T3 (en) | 2017-10-16 |
EP2224917A1 (en) | 2010-09-08 |
KR20100105841A (ko) | 2010-09-30 |
HRP20171476T1 (hr) | 2017-12-15 |
US20090149446A1 (en) | 2009-06-11 |
PL2224917T3 (pl) | 2018-02-28 |
JP2011504490A (ja) | 2011-02-10 |
CA2744736A1 (en) | 2009-06-04 |
US20130172321A1 (en) | 2013-07-04 |
SI2224917T1 (sl) | 2017-12-29 |
US20170128432A1 (en) | 2017-05-11 |
CN101925352A (zh) | 2010-12-22 |
US20180303818A1 (en) | 2018-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2224917T3 (pl) | Kompozycja zawierająca nikotynę oraz opipramol i jej zastosowanie | |
AP2965A (en) | Therapeutic compositions and the use thereof | |
AP2490A (en) | Therapeutic compositions and the use thereof | |
GB0701426D0 (en) | Compounds and their use | |
EP2128196A4 (en) | POLYMERIC COMPOSITION AND APPLICATION THEREOF | |
ZA201004239B (en) | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | |
PL2066408T3 (pl) | Kompozycja na bazie ksantoksyliny i jej zastosowanie w kosmetyce | |
GB0717376D0 (en) | Composition and manufacture thereof | |
EP2077262A4 (en) | IMINOPYRIDINE DERIVATIVES AND THEIR USE | |
EP2213675A4 (en) | PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF | |
PL2012805T3 (pl) | Kompozycja lecznicza i jej zastosowanie | |
EP2069371A4 (en) | ORGANO ARSENOXIDE COMPOUNDS AND THEIR USE | |
EP2133326A4 (en) | NEW PSEUDOGLYCOLIPID AND ITS USE | |
GB0718718D0 (en) | Compound and use thereof | |
ZA200807390B (en) | Topical composition and use thereof | |
GB0714500D0 (en) | composition and treatment | |
GB2461611B (en) | Composition and use thereof | |
EP2168951A4 (en) | AZOLYLMETHYLIDENHYDRAZINE DERIVATIVE AND ITS USE | |
IL205998A (en) | Preparations that include nicotine and opipramol and methods for using them | |
HU0600122D0 (en) | New compounds and their use | |
GB0711036D0 (en) | Composition and their use | |
GB0810409D0 (en) | Composition and use thereof | |
GB0808877D0 (en) | Composition and use thereof | |
GB0720524D0 (en) | Compositions and their use | |
GB0720518D0 (en) | Compositions and their use |